data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Ovid Therapeutics

(NASDAQ:OVID)

Intraday

$3.15

-0.08[-2.48%]

After-Hours

$3.15

0[0.00%]

Perks Buy Compare Brokers

$3.15

-0.08[-2.48%]

At close: Apr 22

$3.15

0[0.00%]

After Hours: 4:01PM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Ovid Therapeutics Stock (NASDAQ:OVID)

Ovid Therapeutics Stock (NASDAQ: OVID)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, April 05, 2024

Wedbush Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $8
Benzinga Newsdesk - Apr 5, 2024, 4:53AM

Thursday, March 21, 2024

Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Avi Kapoor - Mar 21, 2024, 6:45AM

Friday, March 08, 2024

Recap: Ovid Therapeutics Q4 Earnings
Benzinga Insights - Mar 8, 2024, 8:05AM
Ovid Therapeutics Q4 2023 GAAP EPS $(0.220) Misses $(0.100) Estimate, Sales $141.562K Beat $56.500K Estimate
Benzinga Newsdesk - Mar 8, 2024, 8:04AM

Thursday, January 11, 2024

Ovid Therapeutics Filed U.S. Patent Application #20240009160: Use Of (S)-3-amino-4-(Difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid In The Treatment Of Cancer
Charles Gross - Jan 11, 2024, 10:49AM

Thursday, December 21, 2023

BTIG Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $11
Benzinga Newsdesk - Dec 21, 2023, 7:14AM

Wednesday, November 15, 2023

Ovid Therapeutics Inc Says May Offer And Sell Shares Of Our Common Stock Having An Aggregate Offering Price Of Up To $75M From Time To Time
Benzinga Newsdesk - Nov 15, 2023, 4:17PM

Friday, November 03, 2023

Ovid Therapeutics Inc Files For Mixed Shelf Of Up To $250M
Benzinga Newsdesk - Nov 3, 2023, 4:12PM
Ovid Therapeutics Q3 EPS $(0.16) Beats $(0.19) Estimate, Sales $109.00K Beat $50.00K Estimate
Benzinga Newsdesk - Nov 3, 2023, 8:16AM

Wednesday, October 18, 2023

Ovid Therapeutics and Ligand Pharma Ink a $30M Deal for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026
Benzinga Newsdesk - Oct 18, 2023, 8:04AM

Monday, August 21, 2023

Marinus Pharmaceuticals Said On August 17, The PTAB Granted Co's Petition Seeking Post-grant Review Of Ovid Therapeutics' U.S. Patent No. 11,395,817
Charles Gross - Aug 21, 2023, 7:05AM

Friday, August 04, 2023

Ovid Therapeutics' Q2 Cash, Cash Equivalents And Marketable Securities Of $96.5M To Fund Operations Into 2025
Benzinga Newsdesk - Aug 4, 2023, 8:06AM
Ovid Therapeutics Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $75.00K Beat $50.00K Estimate
Benzinga Newsdesk - Aug 4, 2023, 8:05AM

Monday, June 26, 2023

Ovid Therapeutics Added To Russell 3000 Index
Bill Haddad - Jun 26, 2023, 8:11AM

Wednesday, June 14, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Benzinga Insights - Jun 14, 2023, 11:01AM
JonesTrading Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 14, 2023, 5:19AM

Monday, May 22, 2023

Ovid Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - May 22, 2023, 10:45AM

Friday, May 05, 2023

Ovid Therapeutics: Q1 Earnings Insights
Benzinga Insights - May 5, 2023, 9:25AM
Ovid Therapeutics' Cash Balance Of $117.7M Is Expected To Provide Cash Runway To Fund Operations Into 2025 Without Additional Funding
Benzinga Newsdesk - May 5, 2023, 7:34AM
Ovid Therapeutics Q1 EPS $(0.19) Misses $(0.17) Estimate, Sales $66.16K Beat $20.00K Estimate
Benzinga Newsdesk - May 5, 2023, 7:32AM

Tuesday, May 02, 2023

Ladenburg Thalmann Reiterates Buy on Ovid Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk - May 2, 2023, 11:54AM

Monday, May 01, 2023

Ovid Therapeutics And Graviton Bioscience Collaborated To Develop Selective ROCK2 Inhibitors Rare Neurological Diseases, Ovid Will Invest $10M In Preferred Equity In Graviton, And Fund Development Programs
Benzinga Newsdesk - May 1, 2023, 6:04AM

Thursday, April 27, 2023

Ovid Therapeutics Announces Long-Term Safety, Efficacy Findings From Open Label Extension Study
Benzinga Newsdesk - Apr 27, 2023, 2:32PM

Wednesday, April 12, 2023

New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
Vandana Singh - Apr 12, 2023, 9:46AM

Tuesday, April 11, 2023

Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
Vandana Singh - Apr 11, 2023, 2:28PM
Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension
Vandana Singh - Apr 11, 2023, 7:48AM

Wednesday, March 15, 2023

Looking Into Ovid Therapeutics's Return On Capital Employed
Benzinga Insights - Mar 15, 2023, 10:47AM

Monday, March 13, 2023

Ovid Therapeutics' 2022 Cash, Cash Equivalents & Marketable Securities Of $129M; Cash Runway Expected Into 1H 2025
Benzinga Newsdesk - Mar 13, 2023, 8:06AM
Ovid Therapeutics Q4 EPS $(0.16) Beats $(0.18) Estimate, Sales $46.28K
Benzinga Newsdesk - Mar 13, 2023, 8:05AM

Wednesday, March 08, 2023

Studies Published In Cell Reports Medicine Validate The Potential Of Direct KCC2 Activation In Resistant Seizures
Happy Mohamed - Mar 8, 2023, 8:23AM

Thursday, January 05, 2023

Ovid Therapeutics Dosed Healthy Volunteers With OV329 In Phase 1 Trial
Benzinga Newsdesk - Jan 5, 2023, 8:05AM

Tuesday, November 08, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Nov 8, 2022, 12:52PM
Ovid Therapeutics Q3 EPS $(0.17), Same YoY
Benzinga Newsdesk - Nov 8, 2022, 8:06AM

Monday, November 07, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Nov 7, 2022, 12:47PM

Wednesday, October 12, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Oct 12, 2022, 1:32PM

Tuesday, October 11, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 11, 2022, 12:47PM

Monday, August 29, 2022

Citigroup Maintains Neutral on Ovid Therapeutics, Raises Price Target to $2.5
Benzinga Newsdesk - Aug 29, 2022, 7:32AM

Tuesday, August 09, 2022

Ovid Therapeutics Q2 EPS $(0.21) Up From $(0.23) YoY
Benzinga Newsdesk - Aug 9, 2022, 8:16AM

Tuesday, June 21, 2022

Ovid Therapeutics Granted U.S. Patent #11,364,228 Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
Charles Gross - Jun 21, 2022, 10:18AM

Thursday, May 26, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - May 26, 2022, 12:15PM

Monday, May 23, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - May 23, 2022, 12:12PM

Friday, May 20, 2022

Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $2.4
Benzinga Newsdesk - May 20, 2022, 7:13AM

Monday, May 16, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - May 16, 2022, 1:59PM

Wednesday, May 11, 2022

Ovid Therapeutics On May 10, Takeda Notified Co Takeda Planned To Announce Two Pivotal Phase 3 Programs Evaluating Soticlestat Are Likely To Be Delayed
Bill Haddad - May 11, 2022, 8:29AM

Tuesday, May 10, 2022

Ovid Therapeutics: Q1 Earnings Insights
Benzinga Insights - May 10, 2022, 9:07AM
Ovid Therapeutics Q1 EPS $(0.23) Down From $2.53 YoY, Sales $1.40M Down From $208.38M YoY
Bill Haddad - May 10, 2022, 8:11AM

Monday, April 11, 2022

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Apr 11, 2022, 10:49AM

Tuesday, March 22, 2022

Ovid Therapeutics Shares See Recent Volume As Traders Circulate Previously Reported Patent Titled 'Methods for treating aggression associated with Alzheimer's disease'
Benzinga Newsdesk - Mar 22, 2022, 12:36PM
Ovid Therapeutics Granted U.S. Patent #11,278,529 Methods for treating aggression associated with Alzheimer's disease
Charles Gross - Mar 22, 2022, 6:52AM

Tuesday, March 15, 2022

Ovid Therapeutics Q4 EPS $(0.38) Misses $(0.16) Estimate
Bill Haddad - Mar 15, 2022, 8:23AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved